Skip to main content

5 Result(s)

within Sarah W. S. Ng Remove this filter

and

  1. Article

    Open Access

    Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer

    No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests bu...

    Nicolette M. Fonseca, Corinne Maurice-Dror, Cameron Herberts… in Nature Communications (2024)

    Download PDF (21348 KB) View Article

  2. No Access

    Article

    Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genoty**

    De novo metastatic prostate cancer is highly aggressive, but the paucity of routinely collected tissue has hindered genomic stratification and precision oncology. Here, we leveraged a rare study of surgical in...

    Evan W. Warner, Kim Van der Eecken, Andrew J. Murtha, Edmond M. Kwan… in Nature Cancer (2024)

  3. Article

    Open Access

    A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes

    Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predi...

    Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng… in npj Precision Oncology (2023)

    Download PDF (3920 KB) View Article

  4. No Access

    Article

    Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer

    Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer genoty** and longitudinal disease monitoring1. However, owing to past emphasis on targeted and low-resolution profiling app...

    Cameron Herberts, Matti Annala, Joonatan Sipola, Sarah W. S. Ng, **nyi E. Chen… in Nature (2022)

  5. No Access

    Article

    Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer

    Genomic alterations in metastatic castration-resistant prostate cancer can be identified in plasma circulating tumour DNA. A large cohort analysis shows reliable detection of clinically relevant alterations th...

    Sarah W. S. Ng, Alexander W. Wyatt in Nature Reviews Urology (2021)